1. Home
  2. AXS vs BLTE Comparison

AXS vs BLTE Comparison

Compare AXS & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axis Capital Holdings Limited

AXS

Axis Capital Holdings Limited

HOLD

Current Price

$96.07

Market Cap

7.3B

Sector

Finance

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$147.79

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXS
BLTE
Founded
2001
2018
Country
Bermuda
United States
Employees
1966
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3B
6.2B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AXS
BLTE
Price
$96.07
$147.79
Analyst Decision
Buy
Strong Buy
Analyst Count
8
7
Target Price
$121.29
$198.00
AVG Volume (30 Days)
507.2K
164.0K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
1.80%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.53
N/A
Revenue Next Year
$6.95
$492.11
P/E Ratio
$8.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$88.07
$56.68
52 Week High
$110.34
$200.00

Technical Indicators

Market Signals
Indicator
AXS
BLTE
Relative Strength Index (RSI) 39.94 47.82
Support Level $94.12 $148.00
Resistance Level $99.01 $168.44
Average True Range (ATR) 2.28 8.48
MACD -0.40 0.62
Stochastic Oscillator 24.77 58.23

Price Performance

Historical Comparison
AXS
BLTE

About AXS Axis Capital Holdings Limited

Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States (U.S.), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of Insurance and Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States, and also has its presence in Ireland, Lloyd's of London, and Bermuda.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: